“It Was Not My Aim to Sleep There”: The Impact of Timing and Location of Sex on Adherence to Coitally-Dependent HIV Pre-exposure Prophylaxis

The FACTS 001 trial found that vaginal pre- and post-coital application of 1% tenofovir gel did not prevent HIV-1 infection amongst young South African women. The trial included a multi-faceted approach to adherence support and collected objective and self-reported adherence measures. Using qualitat...

Full description

Saved in:
Bibliographic Details
Published inAIDS and behavior Vol. 22; no. 11; pp. 3692 - 3704
Main Authors Scorgie, Fiona, Stadler, Jonathan, Baron, Deborah, Ju, Susan, Ikaneng, Tshepiso, Mabude, Zonke, Makgopa, Sylvia, Malefo, Matshidiso A., Manenzhe, Kgahlisho N., Mazibuko, Thulani, Ntjana, Hilda, Nkala, Busi, Palanee-Phillips, Thesla, Gray, Glenda, Rees, Helen, Delany-Moretlwe, Sinead
Format Journal Article
LanguageEnglish
Published New York Springer US 01.11.2018
Springer Nature B.V
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:The FACTS 001 trial found that vaginal pre- and post-coital application of 1% tenofovir gel did not prevent HIV-1 infection amongst young South African women. The trial included a multi-faceted approach to adherence support and collected objective and self-reported adherence measures. Using qualitative data collected from a random sub-set of FACTS 001 participants (135 in-depth interviews at product discontinuation and 13 focus group discussions at dissemination of trial results), we explore the importance of ‘place’ and ‘timing’ in shaping acts of sexual intimacy and product adherence. Demographically, this qualitative sub-sample is similar to the trial cohort of predominantly young, unemployed women living with parents or other family members. Sexual intimacy was largely unpredictable and happened across multiple locations in which women had limited privacy, autonomy, or control over the timing of sex. This made adherence to the dosing strategy challenging. Findings may inform the development of future event-driven pre-exposure prophylaxis regimens or products.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:1090-7165
1573-3254
DOI:10.1007/s10461-018-2195-1